
    
      This is a randomized, placebo-controlled, double-blind phase 2 trial evaluating approximately
      76 subjects with symptomatic AERD on the safety and efficacy of 8 weeks of oral ifetroban
      treatment. Eligible AERD subjects will be randomized to receive 8 weeks of either oral
      ifetroban daily or matching placebo followed by a 2-week post-treatment period.
    
  